In this session, we’ll take a look back at the evolution of point-of-care testing in the last several decades and how it has shaped the role of the point-of-care coordinator. Then, we’ll break down the responsibilities of the POCT coordinator and offer some insights on what tools vendor reps can develop to offer support to a POCT program.

So few women have access to OB/GYN care locally. AI diagnosis in a family practice office may hold the solution. This talk will explore the impact that self-collection and drop-off of specimens plus the potential for more point-of-care testing using artificial intelligence can have in giving women better access to healthcare.

The presentation explores the synergy between smart point-of-care testing (POCT) technologies and Generative AI. By leveraging these tools, novel models for collaborative and integrated care systems emerge, revolutionizing healthcare delivery. This interdisciplinary approach promises to enhance diagnostic accuracy, streamline processes, and optimize patient outcomes. By embracing innovation at the intersection of healthcare and technology, this approach aims to redefine standards in healthcare delivery and prioritize patient-centered care.

This talk will cover the current status of implementation of oncology screening technologies as they relate to different cancers and to countries at different income levels within the World Bank-designated group of nations who fall into the general category of low- and middle-income countries. It will also address ways in which these countries are planning to address the rising incidence of cancer as the lifestyle of their populations improves.

Advancements in PCR technology hold great promise for point-of-care oncology testing, offering rapid and accurate detection of crucial biomarkers. Meridian’s unique and innovative technologies streamline workflows, enable precise allelic discrimination, and have compatibility with lyophilization bringing oncology testing closer to the patient, enhancing its accessibility. These novel chemistries detect biomarkers directly from various samples without extraction and with exceptional sensitivity, revolutionizing genetic testing and bringing faster genotyping to point-of-care settings.

Precision medicine is exciting everyone in healthcare because personalized companion diagnostics and pharmacogenetics are becoming the norm. Day after day there is an impressive list of very expensive and targeted therapies being approved by regulatory bodies and many more are in the pipeline. Testing prior to treatment or testing prior to trial of drugs will remain an important paradigm in field of CDx. 

Pharmacogenetic testing at point-of-care is poised to revolutionize the field of CDx. Case studies of successful pharmacogenetic technologies at POC and collaboration between pharmaceutical and diagnostics companies to commercialize these PGx solutions will be presented.